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Background: Korean Red Ginseng has been used as a traditional oriental medicine to treat illness and to
promote health for several thousand years in Eastern Asia. It is widely accepted that ginseng saponins,
ginsenosides, are the major active ingredients responsible for Korean Red Ginseng’s therapeutic activity
against many kinds of illness. Although the crude saponin fraction (CSF) displayed antiplatelet activity,
the molecular mechanism of its action remains to be elucidated.
Methods: The platelet aggregation was induced by collagen, the ligand of integrin aIIbI and glycoprotein
VI. The crude saponin’s effects on granule secretion [e.g., calcium ion mobilization and adenosine
triphosphate (ATP) release] were determined. The activation of mitogen-activated protein kinases
(MAPKs), including extracellular signal-regulated protein kinase 1/2 (ERK1/2), c-Jun N-terminal kinases
(JNKs), and p38 MAPK, and phosphoinositide 3-kinase (PI3K)/Akt was analyzed by immunoblotting. In
addition, the activation of integrin aIIbbIII was examined by ﬂuorocytometry.
Results: CSF strongly inhibited collagen-induced platelet aggregation and ATP release in a concentration-
dependent manner. It also markedly suppressed [Ca2þ]i mobilization in collagen-stimulated platelets.
Immunoblotting assay revealed that CSF signiﬁcantly suppressed ERK1/2, p38, JNK, PI3K, Akt, and
mitogen-activated protein kinase kinase 1/2 phosphorylation. In addition, our fraction strongly inhibited
the ﬁbrinogen binding to integrin aIIbb3.
Conclusion: Our present data suggest that CSF may have a strong antiplatelet property and it can be
considered as a candidate with therapeutic potential for the treatment of cardiovascular disorders
involving abnormal platelet function.
Copyright  2015, The Korean Society of Ginseng, Published by Elsevier. All rights reserved.1. Introduction activation of these receptors can stimulate phospholipase C, whichPlatelet aggregation is essential for the normal hemostatic process
when blood vessels are injured. However, aberrant platelet activation
causes cardiovascular diseases such as thrombosis, atherosclerosis,
and myocardial infarction [1]. Several agonists [e.g., collagen,
thrombin, and adenosine diphosphate (ADP)] can bind to glycopro-
tein receptors orG-protein coupled receptors, and lead to subsequent
activation of intracellular downstream signaling molecules. Theysiology and Cell Signaling, College
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ght  2015, The Korean Society ofdecomposes phosphatidylinositol 4,5-bisphosphate into two second
messengers, namely, inositol-1,4,5-trisphosphate (IP3) and diac-
ylglycerol [2,3]. IP3 binds to IP3 receptor of calcium storage pool (i.e.,
dense tubular system) and releases Ca2þ into the cytoplasm. Thus, the
intracellular calcium ion ([Ca2þ]i) concentration can be increased by
more than 10-fold. [Ca2þ]i can bind to the calcium-binding protein
calmodulin and activate myosin light-chain kinase. This kinase cau-
ses the phosphorylation of the regulatory light chain of myosin,of Veterinary Medicine, Kyungpook National University, 80 Daehakro, Bukgu, Daegu
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platelet aggregation occurs and the activation of platelet that goes
beyond this range causes cardiovascular diseases such as thrombosis,
atherosclerosis, and myocardial infarction. Therefore, the suppres-
sion of platelet function by natural products represents a promising
approach to the prevention of thrombosis.
To suppress or prevent the atherosclerosis and thrombosis, many
antiplatelet drugs have been developed [6]. However, these anti-
platelet drugs have had various side effects in some patients, such as
gastrointestinal side effects, hemorrhage, and reduction of platelets
[7e10]. As a result, increasing attention has been paid to dietary
supplements, prevention of cardiovascular diseases for the safety of
drug use, and development of oriental medicines for treatment [11].
Korean Red Ginseng has been used as a traditional oriental
medicine to treat illness and promote health for several thousand
years. Moreover, it is reported that Korean Red Ginseng is an
effective folk medicine against stress, heart failure, hypertension,
diabetes, and so on [12,13]. Korean Red Ginseng contains many
active ingredients such as polysaccharides, peptides, fatty acids,
mineral oils, and ginsenosides. Among these components, ginseng
saponin (i.e., ginsenoside) is one of the well-known bioactive in-
gredients in ginseng, and thus far more than 30 ginsenosides have
been isolated and characterized. Ginsenosides are classiﬁed into
protopanaxadiol (PPD) and protopanaxatriol (PPT) saponins. PPD
includes ginsenoside Rb1 (G-Rb1), G-Rb2, G-Rc, and G-Rd, whereas
PPT contains G-Rg1, G-Re, G-Rf, and G-Rg2.
Although the antiplatelet activities of saponin fraction and
several ginsenosides have been reported [14e17], the molecular
mechanism of its action is not yet well understood.
In this study, we have demonstrated that the crude saponin
fraction (CSF) has strong inhibitory activities on collagen-induced
platelet aggregation. In addition, we determined the molecular
mechanism underlying the antiplatelet activity of CSF.
2. Materials and Methods
2.1. Materials
CSF was obtained from KGC Research Institute (Daejeon, Korea).
CSF was analyzed by HPLC and the composition of ginsenosides is
as follows: 134 mg/g of G-Rg1, 106 mg/g of G-Re, 52 mg/g of G-Rf,
181 mg/g of G-Rb1, 165 mg/g of G-Rc, 108 mg/g of G-Rb2, 18 mg/g of
Rb3, 72 mg/g of Rd, 44 mg/g of F2, 28 mg/g of Rg3. Collagen was
obtained from Chrono-Log Co. (Havertown, PA, USA). Fura-2-
acetoxymethyl ester (Fura-2/AM) and dimethyl sulfoxide (DMSO)
were from Sigma Chemical Co. (St. Louis, MO, USA). Antibodies to
phospho-p44/42 [p-extracellular signal-regulated protein kinase 1/
2 (p-ERK1/2)], p44/42 (T-ERK1/2), phospho-p38 (p-p38), p38 (T-
p38), phospho-SAPK (phospho-stress-activated protein kinase)/c-
Jun N-terminal kinase (p-JNK), SAPK/JNK (T-JNK), phospho-
phosphoinositide 3-kinase (phospho-PI3K; p-p85), PI3K (T-p38),
phospho-mitogen-activated protein kinase kinase (p-MEK1/2),
MEK1/2 (T-MEK1/2), phospho-Akt (p-Akt), and Akt (T-Akt) were
acquired from Cell Signaling Technology (Beverly, MA, USA).
Adenosine triphosphate (ATP) assay kits were purchased from
Biomedical Research Service Center (Buffalo, NY, USA). Fibrinogen
Alexa Fluor 488 conjugate was obtained from Molecular Probes
(Eugene, OR, USA). All other chemicals were of reagent grade.
2.2. Experimental animals
Male Sprague Dawley rats (300e350 g) were obtained from
Orient Co. (Seoul, Korea). The animals were acclimated for 1 wk
before the experiments, and housed in an air-conditioned animal
room with a 12/12-h light/dark cycle at a temperature of 221Cand humidity of 50%  10%. All animals were provided with a lab-
oratory diet and water ad libitum. All experimental protocols
involving the use of animals were conducted in accordance with the
National Institutes of Health guidelines and approved by the Com-
mittee on Animal Care at the Kyungpook National University.
2.3. Washed rat platelet preparation
Blood was withdrawn from the abdominal vein of rats and
collected directly into an anticoagulant citrate dextrose solution
that contained 0.8% citric acid, 2.2% trisodium citrate, and 2%
dextrose (w/v). Washed platelets were prepared as previously
described. In brief, platelet-rich plasma (PRP) was obtained by
centrifuging rat blood samples at 230g for 10 min. Platelets were
precipitated by centrifugation of the PRP at 800g for 15 min and
washed with HEPES buffer (137mM NaCl, 2.7mM KCl, 1mM MgCl2,
5.6mM glucose, and 3.8mM HEPES; pH 6.5) containing 0.35%
bovine serum albumin and 0.4mM ethylene glycol tetraacetic acid
(EGTA). The washed platelets were resuspended in HEPES buffer
(pH 7.4) and the cell dilution was adjusted to 4108 cells/mL.
2.4. Platelet aggregation
Platelet aggregation was evaluated as previously described [18].
Aggregation was monitored by measuring light transmission with
an aggregometer (Chrono-Log Co.) at constant stirring speed
(1,200 rpm). The washed platelets (3108/mL) were preincubated
at 37C for 2 min with either CSF or vehicle and then stimulated
with 2.5 mg/mL collagen. The mixture was further incubated for
5 minwith stirring at 170g. The vehicle concentrationwas less than
0.1% to minimize the effect of this reagent.
2.5. [Ca2þ]i measurement
The intracellular calcium ion concentration ([Ca2þ]i) was
measured with Fura-2/AM as previously described [19]. In brief, the
platelets were incubated with 5mMof Fura-2/AM for 30min at 37C
and washed. The Fura-2-loaded platelets (3108/mL) were then
preincubated with MAE for 2 min at 37C in the presence of 1mM
CaCl2, and subsequently stimulated with collagen for 5 min. Fluo-
rescent signals were recorded using a Hitachi F-2500 ﬂuorescence
spectroﬂuorometer (Hitachi, Japan). Light emission was measured
at 510 nm, with simultaneous excitation at 340 and 380 nm that
changed every 0.5 seconds. Fura-2 ﬂuorescence in the cytosol
measured with the spectroﬂuorometer was calculated as previ-
ously described by Schaeffer and Blaustein [20] using the following
formula: [Ca2þ]i 224nM (F e Fmin)/(Fmax e F), where 224nM is the
dissociation constant of the Fura-2eCa2þ complex, and Fmin and
Fmax represent the ﬂuorescence intensity levels at very low and
very high Ca2þ concentrations, respectively. In our experiment, Fmax
was the ﬂuorescence intensity of the Fura-2eCa2þ complex at
510 nm after the platelet suspension containing 1mM of CaCl2 had
been solubilized with Triton X-100 (0.1%). Fminwas the ﬂuorescence
intensity of the Fura-2eCa2þ complex at 510 nm after the platelet
suspension containing 20mM Tris/3mM of EGTA had been solubi-
lized with Triton X-100 (0.1%). F represented the ﬂuorescence in-
tensity of the Fura-2 complex at 510 nm after the platelet
suspension was stimulated with collagen with or without crude
saponin fraction in the presence of 1mM CaCl2.
2.6. ATP release assay
Washedplatelets (3108/mL)werepreincubated for2minat37C
with various concentrations of CSF and then stimulated with 2.5 mg/
mL collagen. After the reaction was terminated, the cells were
B.R. Jeon et al / Antiplatelet activity of crude saponin fraction 281centrifuged and the supernatantswere used for the assay. ATP release
was measured with a luminometer (GloMax 20/20; Promega, Madi-
son, WI, USA) using an ATP assay kit (Biomedical Research Service
Center, Buffalo, NY, USA) according to manufacturer’s instructions.
2.7. Immunoblotting
Platelet suspensions (3108/mL) were preincubated with CSF or
vehicle [0.1% (v/v) DMSO] at 37C for 2 min. Platelet activation was
induced by the addition of 2.5 mg/mL collagen and the reaction was
allowed to proceed for 5 min. After terminating the reaction, lysates
were then prepared by solubilizing and centrifuging the platelets in
sample buffer [0.125M TriseHCl, pH 6.8; 2% sodium dodecyl sulfate,
2% b-mercaptoethanol, 20% glycerol, 0.02% bromophenol blue, 1 mg/
mL phenylmethyl sulfonyl ﬂuoride, 2 mg/mL aprotinin, 1 mg/mL leu-
peptin, and 1 mg/mL pepstatin A]. Protein concentration was deter-
mined using a bicinchoninic acid assay (Pro-Measure; iNtRON
Biotechnology, Seoul, Korea). Total cell proteins (30 mg) from the
platelet lysate were resolved by 10% sodium dodecyl sulfateepoly-
acrylamide gel electrophoresis and transferred to nitrocellulose
membranes in transfer buffer (25mM Tris, pH 8.5; 0.2M glycine, and
20%methanol). Themembranes were blocked in Tris-buffered saline
and Tween-20 containing 5% nonfat dry milk and incubated with
primary antibody diluted in a blocking solution. The blots were then
incubated with horseradish peroxidase-conjugated secondaryB
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Fig. 1. The inhibitory effect of crude saponin fraction (CSF) on platelet aggregation
induced by collagen. Platelets (3108/mL) were preincubated with or without CSF
(50e400 mg/mL) in the presence of 1mM CaCl2 for 2 min at 37C. The platelet ag-
gregation was then induced by 2.5 mg/mL of collagen, and the extent of aggregation
was measured with a Chrono-Log aggregometer (A). The aggregation reaction was
terminated after 5 min, and the percentage aggregation rate was calculated. Each
graph shows the mean standard deviation of at least four independent experiments
(B). * p< 0.001 compared with the agonist control. Coll, collagen.antibody. Antibody binding was visualized using enhanced chem-
iluminescence (iNtRON Biotechnology).
2.8. Assessment of ﬁbrinogen binding to integrin aIIbb3
Binding of ﬁbrinogen Alexa Fluor 488 conjugate to washed
platelets was quantiﬁed by ﬂow cytometry. In brief, washed
platelets (3108/mL) were preincubated for 2 min with various
concentrations of CSF at room temperature in the presence of
0.1mM CaCl2. The platelets were then stimulated with collagen for
5 min, immediately incubated thereafter with ﬁbrinogen Alexa
Fluor 488 (20 mg/mL) for 5 min, and ﬁnally ﬁxed with 0.5% para-
formaldehyde at 4C for 30 min. The platelets were pelleted by
centrifugation at 2,000g at 4C and resuspended in 500 mL
phosphate-buffered saline. Because the activation of integrin aIIbb3
is largely dependent on the generation of Ca2þ, nonspeciﬁc binding
of ﬁbrinogen to integrin aIIbb3 was measured by assessing ﬁbrin-
ogen binding in the presence of the calcium chelator EGTA (1mM).
The ﬂuorescence of each platelet sample was analyzed using a FACS
Calibur cytometer (BD Biosciences, San Jose, CA, USA), and data
were analyzed using CellQuest software (Becton Dickinson Immu-
nocytometry Systems, San Jose, CA, USA).
2.9. Statistics
Data were analyzed with a one-way analysis of variance fol-
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Fig. 2. (A) The inhibitory effect of crude saponin fraction (CSF) on collagen-induced
[Ca2þ]i. Washed platelets (3108/mL) were incubated with a calcium ﬂuorophore
(5 mM; Fura-2-acetoxymethyl ester) and stimulated with collagen (2.5 mg/mL). [Ca2þ]i
was then measured as described in the “Materials and Methods” section. (B) Effects of
CSF on granule secretion from the collagen-stimulated platelets. Washed platelets
(3108/mL) were preincubated with CSF at the indicated concentrations and stirred in
an aggregometer for 2 min before stimulation with 2.5 mg/mL collagen for 5 min. The
reaction was terminated, and adenosine triphosphate (ATP) release was determined by
ATP assay. Assay was performed as described in the “Materials and Methods” section. Bar
graphs show the mean standard deviation of at least four independent experiments. *
p< 0.05, ** p < 0.005, *** p< 0.001 compared with the agonist control. Coll, collagen.
J Ginseng Res 2015;39:279e285282of the differences observed (SAS Institute Inc., Cary, NC, USA). All
data are presented as the mean standard deviation. A p value of
0.05 or less was considered to be statistically signiﬁcant.
3. Results
3.1. Inhibitory effect of CSF on collagen-induced platelet
aggregation
The concentration of collagen used (i.e., 2.5 mg/mL) could
induce full activation and aggregation of rat platelet. Therefore,
2.5 mg/mL of collagen was used as the ligand to induce plateletColl(2.5 μg/mL)          - +              
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Fig. 3. Effects of crude saponin fraction (CSF) on ﬁbrinogen binding to integrin aIIbb3 in c
integrin aIIbb3 in collagen-activated platelets were measured by ﬂow cytometry. Washed p
centrations ranging from 50 to 400 mg/mL. Collagen was then incubated with human ﬁbrinog
ﬁxed with 0.5% paraformaldehyde at 4C for 30 min. (B) Graphs showing ﬂuorescent inten
trials. Data are expressed as the mean ﬂuorescence intensity of ﬁbrinogen-positive platele
compared with the agonist control. Coll, collagen.aggregation for further experiments. Although washed platelets
were strongly activated by 2.5 mg/mL of collagen in the presence
of 1mM CaCl2, CSF signiﬁcantly inhibited collagen-induced
platelet aggregation in a concentration-dependent manner
(Fig. 1).
3.2. Inhibitory effect of CSF on the granule release
It is well-studied that intracellular calcium ion [Ca2þ]i plays a
critical role in the agonist-induced platelet aggregation. That is,
[Ca2þ]i activates downstream signalingmolecules, and thus, it is the
prerequisite for full activation of platelet. Therefore, we have+              +              +              +
50           100           200          400 
ollagen-activated platelets. (A) The inhibitory effects of CSF on ﬁbrinogen binding to
latelets (3108/mL) were pretreated with vehicle (dimethyl sulfoxide) or CSF at con-
en labeled with Alexa Fluor 488 (20 mg/mL) for 5 minutes. The cells were subsequently
sity present the data from one experiment but are representative of four independent
ts. Each graph presents the results expressed as percentage of gated cells. * p< 0.001
B.R. Jeon et al / Antiplatelet activity of crude saponin fraction 283analyzed the inhibitory effect of CSF on the Ca2þmobilization in rat
platelets. When the platelets were stimulated by collagen, [Ca2þ]i
was signiﬁcantly increased. However, this was markedly dimin-
ished by the pretreatment of CSF in a concentration-dependent
manner (Fig. 2A).
In the following study, we have analyzed whether CSF modu-
lated the ATP granule secretion. Collagen induced ATP release from
dense granules. It was revealed that the pretreatment of platelets
with CSF showed a signiﬁcant decrease in a concentration-
dependent manner (Fig. 2B).
3.3. Inhibitory effect by CSF on the integrin aIIbb3 activation
To prompt intravascular platelet aggregation in a stable manner,
binding of ﬁbrinogen to platelet integrin aIIbb3 should occur.
Therefore, we analyzed the inﬂuence of CSF on integrin aIIbb3
activation using ﬂuorocytometry assay. As shown in Fig. 3, whereas
resting platelet did not activate the integrin aIIbb3, collagen (2.5 mg/
mL) markedly increased the ﬁbrinogen binding to active integrin
aIIbb3. CSF dose-dependently and signiﬁcantly reduced collagen
(2.5 mg/mL)-stimulated ﬁbrinogen binding to integrin aIIbb3.
3.4. Inhibitory effect of CSF on the mitogen-activated protein kinase
phosphorylation
It has been well established that mitogen-activated protein ki-
nases (MAPKs), p38, JNK, and ERK, are acutely, but transiently,
activated by collagen in washed platelets. The activation of MAPK
plays an important role in the secretion of platelet granules. Here,
we determined whether collagen-induced MAPK phosphorylation
could be regulated by CSF. As shown in Fig. 4, CSF suppressedMAPK
phosphorylation in a concentration-dependent manner. Especially,
ERK1/2 phosphorylation was more eminently reduced than others.
3.5. Inhibitory effect of CSF in the phosphorylation of protein
involving PI3K, Akt, and MEK1/2
It is well-known that PI3K and Akt are other important media-
tors of platelet aggregation. We, therefore, investigated whether
CSF modulated PI3K and Akt activation. As shown in Fig. 5, CSF
strongly attenuated PI3K and Akt phosphorylation in a
concentration-dependent manner. In addition, MEK1/2 is anE
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Fig. 4. (A) Effects of crude saponin fraction on collagen-induced phosphorylation of mitogen
with vehicle or crude saponin fraction at the indicated concentration. The platelets were the
total cell proteins were extracted. The proteins were separated by sodium dodecyl sulfateep
membranes were then probed with antibodies against phospho-p44/42, p44/42, phospho-p
chemiluminescence. All immunoblots are representative of three or four independent experi
data are presented as the mean þ/ standard deviation of three or four independent tri
extracellular signal-regulated protein kinase; JNK, c-Jun N-terminal kinase; MAPK, mitogenupstream signaling molecule of MAPK pathway, which is especially
required for ERK1/2 activation. CSF signiﬁcantly reduced collagen-
induced ERK phosphorylation. We then analyzed whether CSF in-
hibits MEK1/2 phosphorylation. As shown in Fig. 5, CSF abolished
MEK1/2 phosphorylation in a concentration-dependent manner.
4. Discussion
Although platelet aggregation is important in the process of
normal hemostasis in the case of damage to blood vessels, aberrant
activation of platelets can cause cardiovascular diseases such as
thrombosis, atherosclerosis, and myocardial infarction [21,22].
Therefore, it is worthwhile to develop antiplatelet drugs isolated
from natural products. Among them, Korean Red Ginseng is a good
candidate for developing antiplatelet agents, because it has been
used in traditional oriental medicine and has various efﬁcacies such
as anti-inﬂammatory, antioxidant, antidiabetic, and liver-
protection functions. Several ginsenosides isolated from Korean
Red Ginseng have been reported to have the function to suppress
platelet activation individually [23,24]. In addition, ginsenoside
from Korean Red Ginseng was also reported to have preventive
effects on cardiovascular diseases. Thus, this study investigated
whether CSF in Korean Red Ginseng suppresses the process of
platelet aggregation and the underlying molecular mechanism of
its antiplatelet action.
Because collagen is a potent agonist for platelet and a component
of subendothelial matrix in blood vessel, it was used to induce
platelet aggregation. As expected, CSF signiﬁcantly and dose-
dependently impaired collagen-induced platelet aggregation. To
elucidate the mechanism of its antiplatelet action, we further
analyzed downstream signaling using intracellular calcium concen-
tration, dense granule secretions, protein phosphorylations (e.g.,
MAPKs and PI3K, Akt), and integrin signaling. A platelet contains
approximately two to seven dense granules, each of which enclose
various substances and coagulation factors, such as ATP, ADP, and
Ca2þ [25,26]. These materials play a crucial role in constricting
damaged blood vessels and aggregating platelets. We found that CSF
signiﬁcantly blocked calcium-ion mobilization and ATP secretion to
a lesser extent in collagen-activated platelets (Fig. 2). This indicated
that CSF impaired dense granule secretion, which is an earlier phase
of platelet activation process. By contrast, the activation process of
integrin aIIbb3 proteins called inside-out signaling is the late and ﬁnal/mL)      - +            + +            +            +     
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Fig. 5. Effects of crude saponin fraction on collagen-induced phosphorylation of PI3K, Akt, and MEK1/2. Washed platelets (3108/mL) were preincubated for 2 min with vehicle or
crude saponin fraction at the indicated concentration. (A) The platelets were then stimulated with 2.5 mg/mL collagen for 5 min at 37C. After terminating the reactions, total cell
proteins were extracted. The proteins were separated by sodium dodecyl sulfateepolyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes. The mem-
branes were then probed with antibodies against phospho-PI3K, phospho-Akt, and phospho-MEK1/2. Antibody binding was visualized by chemiluminescence. (B) The bar graph
shows that the density of speciﬁc band was measured and the data are presented as the mean þ/ standard deviation of three or four independent trials. * p< 0.05, *** p< 0.001
versus vehicle control. Coll, collagen; MEK, mitogen-activated protein kinase kinase; PI3K, phosphoinositide 3-kinase.
J Ginseng Res 2015;39:279e285284stage of platelet activation and aggregation. Moreover, CSF dose-
dependently and signiﬁcantly inhibited the ﬁbrinogen binding to
active integrin aIIbb3 proteins. The principal consequence of adhesion
and activation in platelets is a change in the ligand-binding function
of integrin aIIbb3, which leads to aggregation. This is mediated by
adhesive substrates bound to the membranes of activated platelets.
Therefore, our results indicated that CSF impaired both the earlier
and later phases of platelet activation process.
By contrast, the phosphorylation of signaling molecules,
includingMAPKs (i.e., ERK1/2, p38MAPK, and JNK) and PI3K/Akt are
important steps for outside-in signaling and inside-out signaling
[27,28]. We investigated collagen-induced MAPK phosphorylation
and found that ERK, p38, and JNK are inhibited by CSF
concentration-dependent platelet aggregation. Although the physi-
ological roles of ERK, p38, and JNK are not yet clear, results of many
studies have conﬁrmed that these are associated with the pathway
of integrin aIIbb3 and PLA2/TXA2 [29,30]. In addition, CSF blocked
collagen-induced PI3K/Akt phosphorylation. The PI3K/Akt signaling
pathway is signiﬁcant in platelet activation and aggregation pro-
cesses. The activation of platelet membrane receptor induces the
phosphorylation of PI3K and Akt. Furthermore, it was reported that
PI3K signaling is associatedwith the temporary activation of integrin
aIIbb3. Our results show that collagen-induced PI3K/Akt phosphor-
ylationwas blocked by CSF. In addition, CSF inhibited PI3K activity by
direct enzyme assay, suggesting that the inhibitory acting point of
CSF could be PI3K in the platelet activation and aggregation.
In conclusion, CSF inhibited collagen-induced platelet aggrega-
tion in a concentration-dependent manner. By analyzing down-
stream signaling pathway, we found that CSF blocked granule
secretion and ﬁbrinogen binding to active integrin aIIbb3. In addition,
we found that CSF impaired PI3K/Akt phosphorylation and directly
blocked PI3K enzyme activity, which is the putative acting point of
antiplatelet characterization. Finally, CSF has a potent antiplatelet
activity, suggesting it as a potent natural drug without side effects in
the therapeutic treatment of aberrant platelet activation-related
disorders, including thrombosis, atherosclerosis, and stroke.
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